[Edaily Reporter Son Min-ji] #G2G Bio, a drug delivery system (DDS) platform company, is accelerating its push into the next-generation obesity treatment market by leveraging its long-acting drug delivery technology. G2G Bio is said to be securing a competitive edge by expanding its application scope not only to semaglutide (the active ingredient in Wegovy), which currently dominates the market, but also to dual- and triple-action agents considered next-generation candidates.

Achieving High Concentration and Long-Acting Properties… InnoLAMP Technology Draws Attention

According to the pharmaceutical and biotech industry on the 10th, G2G Bio has completed the development of a one-month sustained-release formulation of GB-7001, an obesity treatment containing semaglutide that utilizes its proprietary microsphere technology, InnoLAMP, and is preparing to submit an Investigational New Drug (IND) application. The submission is expected to take place within the second half of this year. The 3-month sustained-release formulation has also secured most of its preclinical pharmacokinetic (PK) data and is entering the final stages, so an IND submission for that formulation is also expected soon.

Founded in 2017, G2G Bio listed on the KOSDAQ market on August 14 of last year under the technology exception category, leveraging its proprietary InnoLAMP microparticle technology for the development of long-acting pharmaceuticals. “InnoLamp” refers to a long-acting injectable technology designed to load a drug onto microparticles—small spherical particles measuring 10 to 100 micrometers (μm)—and administer them into the body so that the drug is gradually released over a period ranging from several weeks to several months. The core of this technology lies in the microparticles’ ability to retain the drug for an extended period while releasing it at a constant rate. This allows for a reduction in the frequency of dosing while maintaining stable therapeutic effects.

Conventional long-acting microparticle formulations faced challenges such as difficulty in encapsulating high drug concentrations, an initial release phenomenon where the drug is rapidly released immediately after injection, and ensuring reproducibility in the production process. This was because as the drug concentration increased, the drug failed to disperse uniformly within the microparticles and instead accumulated on the surface, leading to greater variability in blood concentrations.

G2G Bio overcame these limitations by using a special porous membrane to produce microparticles of uniform size. The company explains that by mass-producing uniform particles through its proprietary microparticle manufacturing process, it has simultaneously achieved high drug loading, stable drug release, and reproducibility in the production process.

According to data released by G2G Bio, the peak-to-trough ratio (the ratio of peak concentration to trough concentration) for GB-7001 was 1.25, which is lower than that of Ozempic (1.81), a once-weekly formulation. A lower ratio indicates that drug concentrations in the body are maintained more consistently.

Based on this platform technology, G2G Bio’s core pipeline includes not only the aforementioned diabetes and obesity treatment GB-7001, but also the dementia treatment GB-5001 and the postoperative pain treatment GB-6002.

InnoLamp Sets Its Sights on Next-Generation Obesity Drugs

InnoLamp’s potential is expanding further as the global obesity treatment market evolves from GLP-1 monotherapies to dual- and triple-action agents.

G2G Bio presented preclinical data on one-month sustained-release formulations of Cagrisema, Terzepatide, and Retatruotide at the American Diabetes Association (ADA 2026) conference held in New Orleans, Louisiana, from the 5th to the 8th (local time). These drugs have demonstrated weight loss of over 20%, earning recognition for surpassing the “magic 20%” threshold in obesity treatment. Until now, developing long-acting subcutaneous (SC) formulations—which are suitable for self-administration due to their high dosage and dual or triple action mechanisms—has been challenging, but G2G Bio aims to overcome this limitation.

G2G Bio’s signing of a joint research agreement with Samsung Bioepis and Episnex Lab in March—covering a long-acting microsphere drug delivery technology platform—along with a technology transfer agreement for GB-7001, demonstrates the company’s potential to overcome these challenges. The three companies will jointly pursue the development of technology to extend the dosing interval for GLP-1-based obesity treatments to several months. G2G Bio will receive an upfront payment, development and sales milestones, and development funds. Previously, Samsung Bioepis Holdings also invested 20 billion won in convertible bonds (CBs) in G2G Bio.

A biotech industry official stated, “While domestic companies have been recognized for their high level of expertise in microparticle-related technologies, I understand that G2G Bio’s technology has received the highest evaluation among them,” adding, “Given the high unmet need for long-acting obesity treatments, it appears the technology transfer agreement was signed because the company possesses the technology to address this need.”

Global partnerships are also expanding. During its investor relations (IR) presentation last April, G2G Bio disclosed a list of companies with which it is continuing discussions following due diligence—in addition to the global big pharma firms previously announced—including: △ two global companies (Company D, Company E) △ two European companies (Company F, Company G) △ one in Asia (Company H) △ and one in Korea (Company I).

Last year, G2G Bio also signed agreements with Germany’s Boehringer Ingelheim in January and July, respectively, to jointly design and develop long-acting injectable formulations. Although the specific formulation and drug substance have not yet been disclosed, details are expected to be announced soon.

A G2G Bio official stated, “We expect the results of our joint research with Boehringer Ingelheim to be released in the second half of this year. Based on this, we are striving to achieve even better results this year,” adding, “As mentioned during our investor briefing last April, we anticipate that our global partnerships will expand significantly in the future.”